Coverage has ranged from thorough and insightful to boosterish reports on effusive announcements

BIO comes backThere have also been continued consolidation, an accelerated push toward personalized medicine, and a shift to a collaborative business m…

Three Good Things About BIO 2012, and Four Not-so-Good | Xconomy2 days ago … People from all over the world are gathering in Boston today to talk about biotech dreams. Like most years at the Biotec…

In some cases, there was no coverage at all 

BIO 2012 convention bars some, but not all, media from keynote eventThe Globe reported a couple of hours ago that BIO 2012, a trade association's annual convention for the biotech industry, barred repo…

Getting ready to live tweet from #BIO2012 in Boston: Measuring the Impacts of Innovation: What is the Future of Tech Transfer?nature.com Boston

The session seemed to focus on two topics — How to measure the impact of tech tranfer and the impact of the open access movement.

From Bio;”Tech transfer metrics that focus on activity—rather than impact—are a case of the tail wagging the dog. Join a vibrant roundtable discussion on initiatives to create more meaningful metrics, ones that will be useful in developing strategies for future transfers.”  Moderated by James Zanewicz Head of Technology Transfer, Howard Hughes Medical Institute

Zanewicz of HHMI on tech transfer #BIO2012Can researchers commercialize and satisfy the need for #open science?nature.com Boston

Cartier EshamSr. Director Health and Regulatory Affairs, Emerging CompaniesBiotechnology Industry Organization

Cartier Esham of BIO: Open access? Co survey: The ability to obtain exclusive licensing is wildly important. #BIO2012nature.com Boston

Esham of BIO #BIO2012 Tech transfer cornerstone to succees of industry but w/out IP, tech will not be able to obtain fundingnature.com Boston

Esham of BIO #BIO2012 #Openaccess in tech transfer “A solution looking for a problem.”nature.com Boston

Judy Bristow, U of Louisville

Bristow: #BIO2012 If faculty have to provide short-term results to stay funded, projects will be focused on the quick and easy.nature.com Boston

Bristow at U of Louisville #BIO2012 How to measure success of tech transfer? # Patents? # Licenses? $ to university? Impact on society ?nature.com Boston

?er asks:Why not measure success of #techtransfer via patents and inventions? Speakers say measure needs more nuance. #BIO2012nature.com Boston

David WinwoodChief Executive Officer UAB Research Foundation

David Winwood UAB Found:Not every funded research program should be expected to produce an invention or a new co. #BIO2012 #techtransfernature.com Boston

Winwood UAB #BIO2012 #techtransfer If you do this for the money you’ll do it wrong. But if you do it right, the money will follownature.com Boston

More from Nature

Trade Secrets: BIO: Day 1, and Turkey : Trade SecretsDay 1 of BIO Convention. The picture is from above the business partnering section of the conference, located alongside the exhibit hall….

Here in Massachusetts, bio jobs has been a big theme. According to the Globe, the economic downturn took some of the life out ot the state’s life sciences initiative.

Massachusetts life sciences initiative brings fewer jobs than expectedStill, growth in life sciences comes at a time when other sectors have been shrinking. State officials blame the global financial crisis …

Not all bio related jobs are scientific. Joanne Carroll of Somerville serves chowder at the Massachusetts reception. 

bio 4Tinker Ready

The exhibition hall was carnival like or as one reporter saw it…

A Nightmare on BIO 2012 Exhibition StreetBOSTON After crisscrossing the exhibition hall and three Boston zip codes yesterday for my citywide BIO 2012 reception scavenger hunt and…

Tuesday session: ” Academic Medical Centers: The New Pharma R&D Engine and Beyond :Developing 10% of all FDA-approved drug applications, AMCs are indispensible to life sciences. But academia-pharma partnerships are challenging. Looking at case studies of successful collaborations, we’ll uncover new pharma/biotech R&D strategies for partnering directly with AMCs to develop IP.  “

Same old debate — Industry and academics don’t get each other…

Pharma R&D at academic med.cents #BIO2012: Technology will allow AMCs to advance what they do, but must change the culturenature.com Boston

But, new twist — Pharma needs to replenish pipeline; universities need to replenish funding for start-ups now that venture capitalist have lost interest.  

Jonathan Soderstrom, Managing DirectorYale University, Office of Cooperative Research

Soderstrom of Yale: Old tech transfer models don’t work. No VC $ for universities spin offs. Pharma R&D at academic med.cents #BIO2012nature.com Boston

Soderstrom of Yale: Pharma and unies have become desperate in recent years about lack of ability to develop new products #BIO2012nature.com Boston

Conflicts of interest is a barrier, some say. 

Pharma R&D at academic med.cents #BIO2012 Panelists says that excessive concern over conflict of interest gets in the way of collaborationnature.com Boston

Soderstrom Prob. w/ COI committees “You have English professors opining about conflict of interest to a doc at the medical center.”#BIO2012nature.com Boston

How to pick technology that will produce useful products

Therapeutic targets? Soderstrom of Yale: Unies Need outside help: Academics we are not that great at picking winners.#BIO2012nature.com Boston

Gerald McDougall, PricewaterhouseCoopers, LLP

McDougall of PWaterhouse. Unies should use patient advocacy groups w/ laser focus to identify promising new drug targets. #BIO2012nature.com Boston

Bottom line?

McDougall of PWaterhouse. Both industry and academics have to be more strategic and proactive to turn research into new products . #BIO2012nature.com Boston

The locals here really embrace their colonial roots. #BIO2012 https://instagr.am/p/MGMgtRyEhj/Wes Yee